Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose dexamethasone with or without rhTPO for newly diagnosed primary immune thrombocytopenia
ChiCTR1900027735Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Nov 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human thrombopoietin, dexamethasone and prednisone in immune thrombocytopenia (ITP) (2 arms), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Platelet count. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
recombinant human thrombopoietindexamethasoneprednisone
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR1900027735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027735.